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volume can increase as a result of radiosurgery-induced acute transient VS swelling. Therefore, radiosurgery is often avoided in these cases. Surgery is usually advised as a treatment option in large VSs. When performing complete microsurgical removal in these cases, a considerable risk of a suboptimal facial nerve outcome exists and complications are not uncommon. 2, 3, 10, 17, 19, 26, 40, 41, 48, 53 But some patients may present without disabling symptoms. Despite the fact that a large VS is present in the cerebellopontine angle, for example, a patient may not show symptomatology necessitating surgical intervention. In addition, they may present with serviceable hearing. In large VSs, hearing preservation results seem more favorable after radiosurgery 14, 20, 23 than after microsurgery. 6, 12, 35, 39, 40, 48 Some patients may be old or may present with significant comorbidity, making them less than ideal candidates for VS surgery. Finally, some patients may refuse to undergo surgery. Therefore, some patients presenting with large VSs without symptomatic mass effect are candidates for primary radiosurgery. Few studies, all with a relatively small number of patients, have reported on outcomes after GKS for large VSs, 11, 14, 20, 23, 27, 36, 38, 50 and all but two 36, 50 utilized 2D measurements, which are less reliable than volume measurements. 45 We performed the present study to evaluate GKS in a selected group of patients harboring large VSs and to focus on the volumetric growth, control rate, and clinical symptoms after radiosurgery.
Methods

Patient Population
All patients receiving primary GKS for a VS larger than 6 cm 3 between January 1, 2002, and January 1, 2009, were retrospectively analyzed. All VSs at least indented the brainstem, according to the Koos classification ( Fig.  1A and C) . 18 Patients who had undergone microsurgery (16 patients) were excluded from our analysis, leaving 41 patients who underwent primary GKS at the GammaKnife Center Tilburg, St. Elisabeth Hospital. Five patients with neurofibromatosis Type 2 were also excluded and 3 patients were lost to follow-up, leaving a total of 33 patients for study inclusion. The diagnosis of VS was made on a clinical and radiological basis. Patients with Koos Grade III VSs were treated after lesion growth was seen after 1 year of follow-up, whereas intervention without follow-up was planned in patients with Koos Grade IV lesions. Only patients with a VS ≤ 4 cm in the maximum extracanalicular dimension were eligible for primary GKS, because some degree of symptomatic mass effect was usually present. Patients were informed about the diminished reserve to observe growth or transient swelling after radiosurgery, possibly resulting in a higher chance of treatment failure. Subtotal resection followed by GKS for residual VS was also discussed as a possibility. If patients presented with symptomatic mass effect (cerebellar signs, such as dysmetria and truncal ataxia, or long tract signs, such as hemiplegia), they were not considered as candidates for primary GKS; if symptomatic mass effect was present, a subtotal microsurgical removal followed by postoperative GKS was the therapy of choice. These results are published separately. 46 
Surgical Technique
Stereotactic radiosurgery was performed using a Leksell GammaKnife 4C (Elekta AB). Treatment planning was completed with Leksell GammaPlan software (version 8.3.1). A dose of 12.5 to 13.0 Gy (mean 12.6 Gy) was prescribed to the isodose, covering 90% of the tumor volume. The maximum dose varied from 18.1 to 25.5 Gy (mean 20.79 Gy). The tumor margin dose varied from 10.3 to 13 Gy (mean 11.6 Gy). The number of isocenters per patient varied from 3 to 23 (mean 9 isocenters). All patients received 10 mg of dexamethasone intravenously prior to GKS; the dose was tapered off according to a 12-day schedule. All patients could leave the hospital the same day of surgery and resume their daily activities. Follow-up 7 cm 3 ) VS, Koos Grade IV. The patient reported complete unilateral hearing loss and hypesthesia of the maxillary branch of the trigeminal nerve (A). The patient specifically chose treatment with primary GKS. Twenty-four months after radiosurgery the tumor volume was reduced to 4.6 cm 3 (B). Sensibility in the maxillary branch recovered completely, and the patient is functioning well. Axial contrast-enhanced T1-weighted MR images (C and D) obtained in an 83-year-old patient with a large cystic VS (12.9 cm 3 , Koos Grade IV, C). Surgical intervention was not recommended because of severe comorbidity. Therefore, primary GKS was initiated. Preoperative symptoms consisted of unilateral deafness and hypesthesia of the maxillary branch of the trigeminal nerve. After a follow-up of 24 months a significant volume reduction occurred (last volume 2.5 cm 3 , D). The patient is functioning well, and sensibility in the trigeminal nerve is fully recovered.
was planned biannually for the first 2 years and every year thereafter. A clinical chart review was performed to obtain information at presentation and after GKS.
Cranial neuropathy was defined as transient or permanent nerve dysfunction. Audiometric assessments were recorded based on the American Academy of Otolaryngology-Head and Neck Surgery guidelines and consisted of a mean pure tone average (0.5, 1, 2, and 4 kHz) and a speech discrimination score (%). Patients were assigned to hearing Classes A, B, C, or D, where A and B were considered as serviceable hearing and C and D were not. 1 Facial nerve function was scored according to the HB scale. 13 House-Brackmann scores included in this study were noted at the first visit to the outpatient department on presentation and 1 year after GKS. Good postoperative facial nerve function was defined as HB Grade I or II.
One reader experienced in VS imaging performed all radiological evaluations of axial Gd-enhanced (0.1 mg/kg body weight) T1-weighted MR images. The slice thickness was usually 1 or 2 mm, and there was no slice gap. Volume measurements were performed with Leksell GammaPlan software (version 8.3.1). Vestibular schwannoma characteristics were noted as follows: central nonenhancement was defined as a hypointense area in the center of a VS on contrast-enhanced T1-weighted MR imaging. Cystic VSs were defined as VSs with enhanced cysts making up at least one-third of the nonenhancement of the tumor volume on contrast-enhanced T1-weighted and enhancing on T2-weighted MR imaging.
Clinical VS control was defined as no need for further treatment (either GKS or microsurgery) following primary GKS. Radiological control was defined as VS regression or the absence of significant growth beyond a measurement error, which has been defined as a difference of 5.7% between subsequent scans for large VS. 45 
Statistical Analysis
Absolute changes in volume were calculated by subtracting the VS volume at the time of GKS from its volume at the last measurement (volume at t x − volume at t 0 ). Relative changes in volume were calculated as the absolute change divided by the VS volume before GKS (t 0 ): (volume at t x − volume at t 0 )/volume at t 0. This relative change was multiplied by 100 to obtain a percentage change in volume. The cumulative probability of clinical and radiological control was calculated using Kaplan-Meier analyses. Differences in mean values were tested for significance using the independent t-test. The Fisher exact and chi-square tests were used for categorical data. A Cox proportionate hazards model was applied to analyze differences in clinical and radiological control between the patient group that underwent subtotal resection followed by GKS 46 and the group undergoing primary GKS. For all tests, p values < 0.05 indicated statistical significance. All analyses were performed using SPSS 15.0 statistical software (SPSS, Inc.).
Results
Patient and Intervention Characteristics
There were 15 men and 18 women, with a mean age of 54.8 years (range 30-83 years). All patients reported hearing loss on presentation, whereas 12 (36%) of 33 patients presented with serviceable hearing (Class A and B). Twenty-three (70%) patients presented with coexisting tinnitus, 17 (51%) with vertigo, and 12 (36%) with trigeminal hypesthesia. One patient presented with a long history of HB Grade II facial paresis. One presented primarily with diplopia as a result of an abducent nerve paresis due to VS compression. None of the patients presented with symptomatic mass effect. All presented with a large, progressing, unilateral VS with a mean volume of 8.8 cm 3 (range 6.1-17.7 cm 3 ). Before GKS, 1 patient underwent ventriculoperitoneal drainage and 1 underwent lumboperitoneal drainage, because of symptomatic secondary hydrocephalus. Primary GKS was performed in 12 patients because of serviceable hearing, in 17 patients because of patient preference, and in 4 patients because of significant comorbidity. Further clinical and radiological VS features seen at presentation are listed in Table 1 .
Clinical and Radiological Control
Significant VS growth was seen in 4 of 33 patients, resulting in a radiological control rate of 88% of patients. Clinical VS control was achieved in 26 (79%) of 33 cases ( Table 2 ). The median follow-up was 30 months (range 12-72 months). The cumulative probability of clinical and radiological control is shown in Kaplan-Meier analyses (Figs. 2 and 3) . No deaths occurred during the followup. Clinical treatment failure occurred after a mean of 35 months (range 12-52 months). No patient-or VS-related characteristic-age, sex, lesion location, baseline VS size, central nonenhancement, and presence of cystic components-predicted clinical treatment failure, radiological treatment failure, or complications (p = not significant). Two of the 7 instances of clinical failure were treated with a second GKS, and in 5 patients subtotal resection followed by a second GKS was performed (Table 3) . No complications occurred after the second GKS. In 1 patient who underwent a retrosigmoid subtotal resection, facial paralysis occurred despite facial nerve monitoring and microsurgical precision. A sural nerve anastomosis was performed, finally leading to an HB Grade IV paresis. The other 4 patients underwent a translabyrinthine subtotal resection and subsequent GKS without complications. After a median period of 12 months after the second intervention, no VS growth was seen.
Cranial Nerve Preservation
One year post-GKS, good facial nerve function (HB Grades I and II) was preserved in 100% of the patients (Table 4 ). In the 12 patients who had presented with serviceable hearing, 7 (58%) retained their functional hearing during a median follow-up of 37.2 months. Of the 12 patients experiencing trigeminal hypesthesia at diagnosis, 11 (92%) of the 12 patients demonstrated resolution of their condition during the follow-up. The abducent paresis in 1 patient resolved after GKS and the VS shrank.
Patient Complications
There were no major complications after GKS, al-though minor complications did occur (Table 5) : 2 patients experienced HB Grade II transient facial paresis. Three patients experienced transient facial hypesthesia, and 1 of them also exhibited progressive VS growth for which surgical intervention was necessary. Two patients needed ventriculoperitoneal drainage because of symptomatic hydrocephalus 6 and 12 months after GKS, respectively, even in the absence of significant lesion growth. Although there was no significant VS growth, papilledema and progressive ataxic gait developed in 1 patient, and microsurgical subtotal removal followed by GKS was finally performed. Additional steroid treatment was needed after GKS in 6 (18%) of 33 patients with new or worsened neurological symptoms.
Postradiosurgical Growth Patterns
After GKS, 3 volume-changing patterns were iden- 
lesions). Transient swelling occurred after a mean of 8 months after GKS (range 6-12 months). Regrowth following shrinkage was observed after a mean of 37 months (range 24-48 months). Central nonenhancement was seen in 30 (91%) of VSs after GKS. Five (83%) of 6 patients
with VS growth (continuous or after shrinkage) showed central nonenhancement, as compared with 25 (93%) of 27 without growth, which was not statistically significant (p = 0.46). Four patients showed cystic components at the start of GKS; during follow-up, the lesions shrank in 2 patients and remained stable in 2.
Discussion
In large VSs, intervention is often necessary because life-threatening symptomatology can occur as a result of further tumor growth. Radiosurgery is generally not performed given the risk of acute transient swelling, which can lead to additional symptomatic brainstem compression. Microsurgery is generally considered the treatment of choice. However, when performing complete microsurgical removal of large VSs, complications occur frequently, a suboptimal facial nerve outcome is the rule more than the exception, 3, 10, 17, 19, 26, 40, 48, 53 and the preservation of serviceable hearing (if present) is unlikely. 6, 12, 35, 39, 40, 48 In anticipation of these suboptimal facial nerve outcomes, some authors have opted to perform subtotal resection to reduce the risk of facial nerve dysfunction, followed by GKS for remnant tumor to reduce the chance of lesion regrowth. 16, 46 We reported on subtotal resection followed by GKS for large symptomatic VSs, with a 92% clinical control rate, a 94% rate of good facial nerve function preservation during follow-up, and a minimal risk of complications. 46 Nonetheless, the risk of death in VS surgery, which has been reduced over the past decades in response to superior microsurgical skills, is around 1%, even at the most experienced centers. 2, 41 Some patients may present with a large VS on MR imaging but without disabling symptoms and mass effect. In addition, serviceable hearing may be present. Other patients may be physically unfit to undergo VS microsurgery as a result of severe comorbidity. Large studies have shown excellent results for growth control in small/ medium VSs after primary GKS with minimal morbidity. 5, 8, 11, 25, [31] [32] [33] 36, 52 This fact supported our rationale for the treatment featured in the present study. In a selected group of patients presenting with large VSs without symptoms of mass effect, microsurgical removal can be avoided, and primary GKS can control lesion growth and better preserve cranial nerve function.
Growth Control
A limited number of studies on radiosurgery as the primary treatment for large VSs have been conducted (Table 6). 11, 14, 20, 23, 27, 36, 38, 50 Growth control rates vary from 57% to 100%. Measurements were obtained with less reliable 2D measurements in nearly all of these studies, 11, 14, 20, 23, 27, 38 and only 2 studies used volume measurements. 36, 50 In addition, patients with previous VS-related treatments were included in all of the studies, as were follow-ups with CT scanning 14, 27, 36 and patients with neurofibromatosis Type 
2.
14,27 Therefore, a direct comparison of these studies is difficult. These confounders are not part of the current study. Radiological control was achieved in 88% of the patients, and clinical control was achieved in 79%. The lower clinical control rate was due to several reasons, illustrating the diminished reserve to observe growth or transient swelling of large VSs after GKS. First, one patient underwent surgery in the absence of lesion growth because of severe symptomatology. Second, 2 patients had interventions because of tumor regrowth not above the starting volume, without symptomatology. Note that in the absence of life-threatening symptomatology (Table  3) , 4 patients underwent interventions based on radiological growth, not above the starting volume per se. A more reserved attitude toward intervention in cases of asymptomatic growth-by performing MR imaging and clinical follow-up more frequently and by taking into account the possibility of transient swelling-might on the one hand have provided a better clinical control rate of up to 91%, exceeding the radiological growth control rate. On the other hand, this could carry a higher risk of life-threatening symptoms. Our results are comparable with those in other studies reporting radiological growth control in large VSs. Radiological control occurred in 87% of the published cases (150 of 173 cases). 11, 14, 20, 23, 27, 36, 50 There was no difference between clinical and radiological control, as seen in the present series. Two studies documented worse growth control in the largest subset of large VSs, which was not the case in our series. 11, 50 No patient-or VS-related factors predicted radiological or clinical failure.
Three main radiological growth patterns were identified: 1) shrinkage (67%), subdivided into direct shrinkage (55%) and transient swelling followed by shrinkage (12%); 2) stability (21%), subdivided into continuous stable VS (15%) and shrinkage followed by regrowth not above baseline volume (6%); and 3) growth (12%), which was subdivided into continuous growth (6%) and shrinkage followed by regrowth above the baseline volume (6%). Transient swelling occurred at a mean of 8 months (range 6-12 months) and, as mentioned before, should not be confused with continuous growth to prevent unnecessary interventions. Regrowth after shrinkage was observed after a mean of 37 months (range 24-48 months). Central nonenhancement, a reaction due to GKS and previously defined as a good prognostic factor for growth control, 21, 36 did not, in fact, prove to be a prognostic factor indicating growth control. Cystic VSs have been regarded as difficult to treat with GKS given the increased risk of a rapid volume increase, 4,30,47 which was not seen in the present study. The volumetric response of large VSs after GKS resembles the response of small/medium VSs in primary radiosurgery. 28 No patient-or VS-related characteristics correlated with treatment failure.
Cranial Nerve Morbidity and Complications
During follow-up, serviceable hearing and facial and trigeminal nerve function were preserved in 58%, 91%, and 86% of patients, respectively (Tables 4 and 5 ). All newonset facial and trigeminal neuropathies were transient. Ninety-two percent of the patients reporting facial hypesthesia pre-GKS recovered during follow-up. Because of symptomatic secondary hydrocephalus, 2 patients needed ventriculoperitoneal drainage following GKS, despite the absence of significant tumor growth. Rates of facial and trigeminal neuropathies, as well as the occurrence of hydrocephalus for which drainage was necessary, are higher than the rates following GKS for small/medium VSs, which are described in < 1% of cases. 5, 8, 11, 25, [31] [32] [33] 36, 52 Risk factors for trigeminal and facial neuropathies include radiation doses and VS volume. 7, 15, 49 As shown in Table 6 , few studies have reported on cranial nerve preservation after GKS in large VSs, making comparisons difficult. Clearly, facial nerve outcome is superior, compared with the results following complete microsurgical removal of large VSs in which good function (HB Grade I or II) is reported in 28%-58% of cases. 3, 10, 17, 19, 26, 40, 48, 53 Facial nerve outcome is comparable with that in studies featuring subtotal resection followed by GKS. 9, 16, 29, 46, 51 Only 5 studies have documented serviceable hearing preservation after primary GKS in large VS. Forty-one (71%) of the 58 patients in these studies retained serviceable hearing after follow-up. 14, 20, 23, 27, 36, 50 These results are in line with those obtained in the present study and are superior to the published range of hearing preservation rates following complete microsurgical removal of large VSs (0%-29%). 6, 12, 35, 39, 40, 48 Hearing loss after GKS is caused by the toxic effects of GKS on the cochlea, 43, 44 which is almost unavoidable when planning for GKS. If possible, the treatment plan is modified to minimize the dosage to the cochlea. No large studies have documented hearing preservation after subtotal resection. No patientor VS-related factors predicted complications.
Study Considerations
Primary GKS for large VSs has shown reasonable growth control and complication rates in the present series of selected patients. Arguments against this treatment strategy are that radiosurgery causes an increased risk of complications as a result of swelling and that microsurgery following GKS would be more complicated than primary microsurgery. Indeed, an increased postradiosurgical morbidity rate was seen after GKS, when compared with GKS for smaller VSs. 5, 8, 11, 25, [31] [32] [33] 36, 52 When choosing GKS for large VSs, extensive patient instructions are obligatory before radiosurgery, as are close clinical and radiological follow-ups at least every 6 months in the first 2 years after the procedure. Previous authors found no clear relationship between prior radiosurgery and a subsequent difficulty in resecting a VS, 34, 37 which has also been our experience. Subtotal resection is advised in the event that one needs intervention after primary GKS. 34, 42 No procedural complications occurred in 4 of 5 patients who underwent microsurgery in this series. In 1 patient a facial nerve paralysis occurred, for which a sural nerve anastomosis was performed. In cases of treatment failure, a second GKS treatment can also be performed effectively, 22, 24 as was the case in our patients.
Study Limitations
This study has some limitations. First, the follow-up time was relatively short. Given the median follow-up (30 months) and the mean time of clinical failure (35 months), we acknowledge that a longer follow-up is necessary to draw definite conclusions. Second, limitation is inherent to a retrospective study, which carries the risk of selection bias.
Subtotal Resection Followed by GKS Versus Primary GKS for Large VSs
After separately analyzing the treatment strategies of subtotal resection followed by GKS 46 versus primary GKS for large VSs, we performed a matched-cohort analysis in which the 2 groups were matched for age and VS volume. Of course, after matching, one still deals with confounding by indication. A hazard ratio of 2.5 (p = 0.17) was found for clinical failure when performing primary GKS. The hazard ratio for radiological failure was 1 (p = 0.94), and so there was no difference between the 2 treatment strategies in terms of radiological growth con- trol. The following conclusion can be drawn when choosing between subtotal resection followed by GKS and primary GKS for large VSs: primary GKS leads to more instances of clinical failure (in part due to the diminished reserve to watch tumor growth or transient swelling) after treatment. Therefore, subtotal resection followed by GKS seems a more secure option than primary GKS for large VSs. In the case of a patient's wishes, in the presence of comorbidity or functional hearing, for a VS smaller than
